NCT04230954View on ClinicalTrials.gov

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 16, 2020

Primary Completion Date

February 16, 2022

Study Completion Date

February 16, 2022

Conditions
Cervical CancerRecurrent Cervical CancerMetastatic Cervical CancerPersistent Cervical Cancer
Interventions
DRUG

Cabozantinib 40 MG oral once a day

Cabozantinib 40 mg oral once a day

DRUG

Pembrolizumab 200 mg IV every 3 weeks

Pembrolizumab 200 mg IV every 3 weeks

Trial Locations (1)

36604

University of South Alabama Mitchell Cancer Institute, Mobile

Sponsors

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

lead

University of South Alabama

OTHER